Sjogren SyndromeFOMONCT06740175
The Feasibility of Multispectral Optoacoustic Tomography in Different Diseases
A study testing Multispectral optoacoustic tomography in people with Sjogren Syndrome and Malignant Tumors, run by University Medical Center Groningen at 1 site in Netherlands.
Trial summary
Optoacoustic imaging is a new and innovative imaging technique that combines the high contrast of optical imaging with the penetration depth and high spatial resolution of ultrasonography using the optoacoustic effect. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sjogren Syndrome, Malignant Tumors, Arterial Disease
- What is being tested?
- Multispectral optoacoustic tomography
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteNetherlands
- Study dates
- 7 Apr 2020to 14 Oct 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients with the following diseases will be included:
- Morbus Sjögren,
- A superficially located malignant tumor \< 5 centimeter beneath the skin
- (Peripheral) arterial disease
- Age ≥ 18 years;
Who cannot join
- Patients with disease localizations or manifestations that do not enable good coupling between the optoacoustic probe and the skin, as decided by the researchers;
- Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
- Pregnant women. Women of childbearing potential need to undergo a pregnancy test before participation.
Trial locations and contacts
1 site in 1 country.
Netherlands1 site
University medical center groningen
Groningen, Provincie Groningen, 9713 GZ
About this study
Official title: The Feasibility of Multispectral Optoacoustic Tomography in Different Diseases: a Phase 1 Explorative Imaging Study (FOMO-study)
Optoacoustic imaging is a new and innovative imaging technique that combines the high contrast of optical imaging with the penetration depth and high spatial resolution of ultrasonography using the optoacoustic effect. It can resolve different endogenous tissue chromophores and may thereby provide insight in molecular changes associated with disease (-progression). It can be potentially used as an technique for diagnosis, treatment monitoring and disease localization. As the technique is relatively new in the clinical setting, there is not much clinical experience with optoacoustic imaging. The rationale for this study is to assess the technical feasibility of optoacoustic imaging in a variety of disease and to determine endogenous biomarkers for disease characterization for potential diagnosis and/or disease monitoring.
Read the detailed description
Optoacoustic imaging is a novel imaging method that is based on the optoacoustic effect, first described by Alexander Graham Bell in 1880. When biological tissue is illuminated with an ultrashort laser pulse, tissue chromophores absorb laser light and form pressure transient waves as a result of thermoelastic expansion. These optoacoustic or photoacoustic waves can be detected by wideband ultrasonic transducers around the tissue. Optoacoustic imaging is unique as it resolves optical contrast, but the resolution obeys the rules of ultrasonic diffraction; scattering of the ultrasonic signal in tissue is much weaker than for optical signals. Therefore, optoacoustic methods are insensitive to photon scattering within biological tissues and thereby provide higher spatial resolution with high sensitivity to tissue light absorption. In addition, it obtains penetration depths up to several centimeters, making it suitable for imaging deeper tissues within the body. Optoacoustic imaging has been shown to address clinically relevant aspects of various diseases, such as multiple prevalent cancers and inflammatory bowel disease.
Multiple imaging methods are based on optoacoustic imaging. However, unlike other types of optoacoustic imaging, multispectral optoacoustic tomography (MSOT) involves illumination of tissue with multiple wavelengths. Due to the high frequency pulse rate of the 9 laser, multiple wavelengths can be identified in one single image. Images can be processed using spectral unmixing algorithms in order to resolve different tissue chromophores, such as hemoglobin, deoxyhemoglobin, melanin and fat, which all have a distinct absorption spectrum or "spectral signature". This provides the ability to reconstruct an image by distinguishing and quantifying the contribution of specific absorbers including endogenous tissue chromophores.
Differences in the distribution of endogenous chromophores between normal tissue and diseased-tissue have been described extensively in preclinical and clinical optoacoustic studies. As the proliferation and metastatic spread in malignant tumors is highly dependent on angiogenesis, differences in hemoglobin concentration between normal tissue and tumor tissue is a well-known pathophysiological phenomenon Abnormal vascularization causing a local increase in hemoglobin concentration produces strong optoacoustic contrast, making optoacoustic imaging suitable for visualization of angiogenesis and tumors. This phenomenon could be used for diagnosis of a variety of malignant tumors, but potentially also for monitoring of disease progression after treatment. For example, relevant differences between hemoglobin distribution in benign and malignant thyroid tissue have been observed and the visualization of breast tumors using otoacoustics has been described.
For peripheral arterial disease, hemoglobin distribution and plaque characteristics are highly relevant biological features in the characterization of the disease. Nowadays, imaging modalities like X-ray CT are considered the gold standard, which give a relevant radiation burden to patients. Optoacoustic imaging has the potential for visualizing for example the peripheral arteries and the carotid artery, even in a 3D setting Identification of specific plaque characteristics like collagen and lipids would be a next step forward in visualization of plaque biology and its relationship with plaque rupture. This is topic of an already approved MSOT protocol in which 5 patients are enrolled.
As MSOT is experiencing a surge of interest in clinical investigation, there have been technological developments that enable imaging systems suitable for clinical use. The MSOT Acuity Echo (iThera Medical GmbH) that we use in the UMCG is dedicated for clinical research and similar to clinical ultra-sound technology in form and handling. Furthermore, it enables additional use of ultrasonography (OPUS) so that it delivers anatomical, functional and molecular information simultaneously. The MSOT Acuity Echo provides immediate feedback in the form of live images.
As multiple disciplines (surgery, radiology, nuclear medicine, oral and maxillofacial surgery, internal medicine) are interested in using the device, we aim to explore the possibilities of MSOT for various indications. We hypothesize that visualizing tissue chromophores with MSOT can lead to identification of molecular changes associated with disease (-progression).
- Conditions
- Sjogren Syndrome, Malignant Tumors, Arterial Disease
- Being tested
- Multispectral optoacoustic tomography
- Keywords
- Multispectral optoacoustic tomography, Optoacoustic imaging, Sjogren syndrome, Diagnostic, Diagnose, Non-invasive
- Medical subject headings
- Sjogren's Syndrome, Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multispectral optoacoustic tomographyDevice
If patients are willing to participate in this study, they are imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo) at the department of nuclear medicine and molecular imaging. The imaging procedure takes 15 minutes at most.
| Study group | Role | What they receive |
|---|---|---|
| Experimental MSOT measurement | Experimental | imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo). Receives: Device: Multispectral optoacoustic tomography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Optoacoustic Signal Analysis
Quantitative assessment of optoacoustic signals from tissue chormophores (e.g., hemoglobine, deoxyhemaglobine, water, lipid, and collagen). The signal of the different chormophores are described as arbitrary units (a.u.)
Measured: After informed consent the patient will be imaged for 15 minutes.
Comparison with Standard Imaging Modalities
Validation of optoacoustic imaging by comparing chromophore signals to imaging features from CT, MRI, PET, and/or ultrasound. Correlation coefficients or diagnostic accuracy metrics (e.g., sensitivity, specificity, area under the curve).
Measured: After informed consent the patient will be imaged for 15 minutes.
Histopathological Correlation
Correlation of optoacoustic findings with histopathological results from biopsy or surgical specimens. Agreement rate or correlation metrics (e.g. p-values)
Measured: After informed consent the patient will be imaged for 15 minutes.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Dec 2024
- Study start7 Apr 2020
- Primary completion14 Oct 2021
- Study completion14 Oct 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sjogren SyndromeStudies of the same condition, open and under way.
- More trials run by University Medical Center GroningenThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Medical Center Groningen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06740175
- Sponsor's protocol ID
- NL71894.042.19
- Acronym
- FOMO
- Status last verified
- Nov 2024
- First submitted
- 7 Nov 2024
- Last updated
- 18 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Relevant research data on request
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Feasibility of Multispectral Optoacoustic Tomography in Different Diseases: a Phase 1 Explorative Imaging Study (FOMO-study)
- ClinicalTrials.gov ID
- NCT06740175
- Acronym / sponsor ID
- FOMO / NL71894.042.19
- Conditions
- Sjogren Syndrome, Malignant Tumors, Arterial Disease
- Keywords
- Multispectral optoacoustic tomography, Optoacoustic imaging, Sjogren syndrome, Diagnostic, Diagnose, Non-invasive
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University Medical Center GroningenUniversity, hospital or other
- Study start
- 7 Apr 2020 (actual)
- Primary completion
- 14 Oct 2021 (actual)
- Study completion
- 14 Oct 2021 (actual)
- First posted
- 18 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Optoacoustic imaging is a new and innovative imaging technique that combines the high contrast of optical imaging with the penetration depth and high spatial resolution of ultrasonography using the optoacoustic effect. It can resolve different endogenous tissue chromophores and may thereby provide insight in molecular changes associated with disease (-progression). It can be potentially used as an technique for diagnosis, treatment monitoring and disease localization. As the technique is relatively new in the clinical setting, there is not much clinical experience with optoacoustic imaging. The rationale for this study is to assess the technical feasibility of optoacoustic imaging in a variety of disease and to determine endogenous biomarkers for disease characterization for potential diagnosis and/or disease monitoring.
Detailed description
Optoacoustic imaging is a novel imaging method that is based on the optoacoustic effect, first described by Alexander Graham Bell in 1880. When biological tissue is illuminated with an ultrashort laser pulse, tissue chromophores absorb laser light and form pressure transient waves as a result of thermoelastic expansion. These optoacoustic or photoacoustic waves can be detected by wideband ultrasonic transducers around the tissue. Optoacoustic imaging is unique as it resolves optical contrast, but the resolution obeys the rules of ultrasonic diffraction; scattering of the ultrasonic signal in tissue is much weaker than for optical signals. Therefore, optoacoustic methods are insensitive to photon scattering within biological tissues and thereby provide higher spatial resolution with high sensitivity to tissue light absorption. In addition, it obtains penetration depths up to several centimeters, making it suitable for imaging deeper tissues within the body. Optoacoustic imaging has been shown to address clinically relevant aspects of various diseases, such as multiple prevalent cancers and inflammatory bowel disease.
Multiple imaging methods are based on optoacoustic imaging. However, unlike other types of optoacoustic imaging, multispectral optoacoustic tomography (MSOT) involves illumination of tissue with multiple wavelengths. Due to the high frequency pulse rate of the 9 laser, multiple wavelengths can be identified in one single image. Images can be processed using spectral unmixing algorithms in order to resolve different tissue chromophores, such as hemoglobin, deoxyhemoglobin, melanin and fat, which all have a distinct absorption spectrum or "spectral signature". This provides the ability to reconstruct an image by distinguishing and quantifying the contribution of specific absorbers including endogenous tissue chromophores.
Differences in the distribution of endogenous chromophores between normal tissue and diseased-tissue have been described extensively in preclinical and clinical optoacoustic studies. As the proliferation and metastatic spread in malignant tumors is highly dependent on angiogenesis, differences in hemoglobin concentration between normal tissue and tumor tissue is a well-known pathophysiological phenomenon Abnormal vascularization causing a local increase in hemoglobin concentration produces strong optoacoustic contrast, making optoacoustic imaging suitable for visualization of angiogenesis and tumors. This phenomenon could be used for diagnosis of a variety of malignant tumors, but potentially also for monitoring of disease progression after treatment. For example, relevant differences between hemoglobin distribution in benign and malignant thyroid tissue have been observed and the visualization of breast tumors using otoacoustics has been described.
For peripheral arterial disease, hemoglobin distribution and plaque characteristics are highly relevant biological features in the characterization of the disease. Nowadays, imaging modalities like X-ray CT are considered the gold standard, which give a relevant radiation burden to patients. Optoacoustic imaging has the potential for visualizing for example the peripheral arteries and the carotid artery, even in a 3D setting Identification of specific plaque characteristics like collagen and lipids would be a next step forward in visualization of plaque biology and its relationship with plaque rupture. This is topic of an already approved MSOT protocol in which 5 patients are enrolled.
As MSOT is experiencing a surge of interest in clinical investigation, there have been technological developments that enable imaging systems suitable for clinical use. The MSOT Acuity Echo (iThera Medical GmbH) that we use in the UMCG is dedicated for clinical research and similar to clinical ultra-sound technology in form and handling. Furthermore, it enables additional use of ultrasonography (OPUS) so that it delivers anatomical, functional and molecular information simultaneously. The MSOT Acuity Echo provides immediate feedback in the form of live images.
As multiple disciplines (surgery, radiology, nuclear medicine, oral and maxillofacial surgery, internal medicine) are interested in using the device, we aim to explore the possibilities of MSOT for various indications. We hypothesize that visualizing tissue chromophores with MSOT can lead to identification of molecular changes associated with disease (-progression).
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Experimental MSOT measurement | Experimental | Device: Multispectral optoacoustic tomographyimaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients with the following diseases will be included:
- Age ≥ 18 years;
Key exclusion criteria (3 listed)
- Patients with disease localizations or manifestations that do not enable good coupling between the optoacoustic probe and the skin, as decided by the researchers;
- Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
- Pregnant women. Women of childbearing potential need to undergo a pregnancy test before participation.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multispectral optoacoustic tomographyIf patients are willing to participate in this study, they are imaged with the multispectral optoacoustic tomography device (MSOT Acuity Echo) at the department of nuclear medicine and molecular imaging. The imaging procedure takes 15 minutes at most. | Device | Experimental MSOT measurement |
Primary outcome
Optoacoustic Signal Analysis
Time frame: After informed consent the patient will be imaged for 15 minutes.
Quantitative assessment of optoacoustic signals from tissue chormophores (e.g., hemoglobine, deoxyhemaglobine, water, lipid, and collagen). The signal of the different chormophores are described as arbitrary units (a.u.)
Comparison with Standard Imaging Modalities
Time frame: After informed consent the patient will be imaged for 15 minutes.
Validation of optoacoustic imaging by comparing chromophore signals to imaging features from CT, MRI, PET, and/or ultrasound. Correlation coefficients or diagnostic accuracy metrics (e.g., sensitivity, specificity, area under the curve).
Histopathological Correlation
Time frame: After informed consent the patient will be imaged for 15 minutes.
Correlation of optoacoustic findings with histopathological results from biopsy or surgical specimens. Agreement rate or correlation metrics (e.g. p-values)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2024.
- Individual participant dataSharing planned: Yes. Relevant research data on request
Related trials for Sjogren Syndrome
RecruitingPhase 2
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
Sjogren's Syndrome
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Active, not recruitingObservational study
Possible Sarcopenia, Sarcopenia, and Functional Status in Patients With Primary Sjögren's Syndrome
Primary Sjögren Syndrome, Sarcopenia
RecruitingPhase 1
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Active, not recruitingPhase 2
Autologous Serum Obtained by a Closed-Circuit Collection Device
GVHD, Meibomian Gland Dysfunction (Disorder)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multispectral optoacoustic tomography in people with Sjogren Syndrome and Malignant Tumors, run by University Medical Center Groningen at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Optoacoustic Signal Analysis (time frame: After informed consent the patient will be imaged for 15 minutes.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2024.